Literature DB >> 6307698

Specific diagnosis of hepatoma using 99mTc-HIDA and other radionuclides.

V W Lee, J H Shapiro.   

Abstract

The difficulty of clinical and radiographical diagnosis of hepatoma is discussed. A case of hepatoma is reported. Both the primary tumor and distant metastases showed strong avidity for 99mTc-HIDA, which normally is concentrated by parenchymal cells of the liver. The potential of using 99mTc-HIDA for the noninvasive investigation of patients suspected of having hepatoma is discussed. The association between tumor avidity for 99mTc-HIDA and the bile-forming ability of tumor cells is of interest.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6307698     DOI: 10.1007/bf00253764

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  22 in total

1.  Roentgenologic manifestations of primary hepatoma with particular reference to some unusual cholecystographic findings.

Authors:  R W BRUST; P C CONLON
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1962-04

2.  Primary and metastatic carcinoma of the liver. Relationship to hepatic cirrhosis.

Authors:  E A GALL
Journal:  Arch Pathol       Date:  1960-08

3.  Direct measurement of hepatic blood flow in surgical patients: with related observations on hepatic flow dynamics in experimental animals.

Authors:  W G SCHENK; J C McDONALD; K McDONALD; T DRAPANAS
Journal:  Ann Surg       Date:  1962-09       Impact factor: 12.969

4.  Concentration and clearance of Tc-99m-pyridoxylidene isoleucine by a hepatoma.

Authors:  K Ueno; Y Haseda
Journal:  Clin Nucl Med       Date:  1980-05       Impact factor: 7.794

5.  Blood pool scanning in investigating hepatic mass lesions.

Authors:  E Lubin; Z Lewitus
Journal:  Semin Nucl Med       Date:  1972-04       Impact factor: 4.446

6.  Functional hepatoma demonstrated with rose bengal scanning.

Authors:  J D Shoop
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1969-09

7.  Diagnosis of hepatoma by scintigraphy using multiple radionuclides.

Authors:  V W Lee; E Estabaya; J H Shapiro
Journal:  J Surg Oncol       Date:  1980       Impact factor: 3.454

8.  Retrospective comparison of radionuclide scans and computed tomography of the liver and pancreas.

Authors:  R L MacCarty; H W Wahner; D H Stephens; P F Sheedy; R R Hattery
Journal:  AJR Am J Roentgenol       Date:  1977-07       Impact factor: 3.959

9.  Clinical applications of ultrasound tissue characterization.

Authors:  A T Rosenfield; K J Taylor; C C Jaffe
Journal:  Radiol Clin North Am       Date:  1980-04       Impact factor: 2.303

10.  Diagnosis of abdominal malignancy by radiologic fine-needle aspiration biopsy.

Authors:  J T Ferrucci; J Wittenberg; P R Mueller; J F Simeone; W P Harbin; R H Kirkpatrick; P D Taft
Journal:  AJR Am J Roentgenol       Date:  1980-02       Impact factor: 3.959

View more
  5 in total

1.  Small hepatocellular carcinoma visualized with technetium-99m(Sn)-N-pyridoxyl-5-methyltryptophan.

Authors:  I Narabayashi; T Hamada; O Aoki; T Suematsu
Journal:  Ann Nucl Med       Date:  1987-09       Impact factor: 2.668

2.  Concentration of 99mTc-Sn-N-pyridoxyl-5-methyltryptophan, a biliary agent, in distant metastases of hepatomas.

Authors:  Y Hasegawa; S Nakano; K Ibuka; T Hashizume; Y Sasaki; S Imaoka; S Ishiguro; S Tanaka; H Kasugai; Y Okano
Journal:  Eur J Nucl Med       Date:  1985

3.  Comparison of delayed hepatobiliary imaging using 99mTc-Sn-N-pyridoxyl-5-methyltryptophan and 67Ga-citrate imaging for diagnosis of hepatocellular carcinoma.

Authors:  Y Hasegawa; S Nakano; S Ishiguro; S Imaoka; Y Sasaki; S Tanaka; H Kasugai; J Kojima; S Ishigami
Journal:  Eur J Nucl Med       Date:  1988

Review 4.  Radionuclide therapy revisited.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1991

5.  Analysis of factors affecting uptake of Tc-99m Sn-N-pyridoxyl-5-methyltryptophan by hepatocellular carcinoma.

Authors:  Y Hasegawa; S Nakano; T Sobue; M Fujita; S Ishiguro; Y Sasaki; S Imaoka; S Tanaka; H Kasugai; A Inoue
Journal:  Ann Nucl Med       Date:  1994-05       Impact factor: 2.668

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.